Reversible restrictive cardiomyopathy due to light-chain deposition disease.
Systemic light-chain deposition due to plasma cell dyscrasias manifests as a form of restrictive cardiomyopathy with diastolic ventricular dysfunction. Although these manifestations are likely to be cardiac amyloidosis, whether these pathological conditions are reversible after treatment of the underlying plasma cell disorders is unknown. To our knowledge, we describe the first patient with cardiac light-chain deposition due to multiple myeloma in whom echocardiographic and biochemical factors of cardiac function were ameliorated dramatically after remission of this disorder. We emphasize that restrictive cardiomyopathy due to light-chain deposition may be reversible and have a relatively better prognosis after remission of plasma cell dyscrasias.
Nakamura
Motoyuki
M
Department of Internal Medicine, Iwate Medical University, Morioka, Japan. nkmrmoto@iwate-med.ac.jp
Satoh
Mamoru
M
Kowada
Shugo
S
Satoh
Hidetoshi
H
Tashiro
Atsushi
A
Sato
Fumitoshi
F
Masuda
Tomoyuki
T
Hiramori
Katsuhiko
K
D000328:Adult; D000855:Anorexia / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols; D001706:Biopsy; D001856:Bone Marrow Examination; D002313:Cardiomyopathy, Restrictive / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D004417:Dyspnea / Q000209:etiology; D004452:Echocardiography; D004562:Electrocardiography; D006439:Hemodynamics; D006801:Humans; D007147:Immunoglobulin Light Chains; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D007147:Immunoglobulin Light Chains; D009607:Nitrosourea Compounds; D014750:Vincristine; D008558:Melphalan; C020766:ranimustine